outgo
lymphat
vessel
cell
reach
bloodstream
transport
tissu
throughout
bodi
upon
patrol
tissu
gradual
drift
back
lymphat
system
reenter
blood
begin
cycl
th
e
complex
pattern
recircul
depend
state
cell
activ
adhes
molecul
express
immun
endotheli
cell
presenc
chemotact
molecul
select
attract
particular
popul
blood
cell
circul
immun
cell
addit
expos
factor
releas
system
wide
rang
molecular
cellular
profi
ling
assay
current
avail
studi
human
immun
system
figur
th
e
level
sophist
instrument
polychromat
fl
ow
cytomet
one
immunologist
favorit
tool
increas
past
year
major
technolog
breakthrough
also
occur
fi
eld
genom
proteom
thu
creat
today
uniqu
opportun
studi
human
be
health
diseas
inher
heterogen
dictat
larg
collect
sampl
analyz
among
highthroughput
molecular
profi
ling
technolog
avail
today
genom
approach
scalabl
breadth
robust
therefor
best
suit
studi
human
popul
th
e
human
genom
investig
two
diff
erent
angl
consist
either
determin
make
measur
output
sequenc
variat
detect
use
instanc
singl
nucleotid
polymorph
snp
chip
permit
identifi
cation
common
polymorph
rare
mutat
associ
diseas
hundr
thousand
snp
type
use
platform
yield
genomewid
hypothesisfre
scan
genet
associ
given
phenotyp
interest
mani
genomewid
associ
studi
often
refer
gwa
publish
recent
year
number
investig
genet
underpin
immunerel
diseas
notabl
studi
use
pinpoint
gene
pathway
may
involv
pathogenesi
figur
blood
pipelin
immun
system
transcript
profi
ling
blood
consist
measur
rna
abund
circul
nucleat
cell
chang
transcript
abund
result
exposur
host
pathogenderiv
immunogen
factor
exampl
pathogenderiv
molecular
pattern
activ
special
pattern
recognit
receptor
express
surfac
leukocyt
andor
chang
rel
cellular
composit
exampl
infl
ux
immatur
neutrophil
occur
respons
bacteri
infect
main
blood
leukocyt
popul
circul
blood
repres
fi
gure
cell
type
special
function
eosinophil
basophil
neutrophil
innat
immun
eff
ector
play
key
role
defens
pathogen
lymphocyt
mediat
adapt
cellular
immun
respons
antibodi
produc
b
lymphocyt
plasma
cell
key
eff
ector
humor
immun
respons
monocyt
dendrit
cell
b
lymphocyt
present
antigen
lymphocyt
play
central
role
develop
adapt
immun
respons
blood
leukocyt
expos
circul
factor
releas
system
tissu
pathogen
process
take
place
addit
leukocyt
cross
endotheli
barrier
reach
local
site
infl
ammat
dendrit
cell
expos
infl
ammatori
factor
tissu
transport
via
lymphat
system
reach
lymph
node
via
aff
erent
lymphat
vessel
dendrit
cell
encount
cell
transport
lymph
node
via
high
endotheli
venul
educ
cell
exit
lymph
node
via
eff
erent
lymph
vessel
collect
thorac
lymph
duct
turn
connect
subclavian
vein
point
cell
rejoin
blood
circul
associ
common
genet
variant
resist
infect
also
report
howev
paramet
measur
approach
determin
hered
chang
throughout
life
individu
th
contrast
transcript
abund
paramet
measur
second
genomewid
profi
ling
approach
transcript
activ
larg
depend
environment
factor
result
rna
abund
chang
dynam
time
instanc
set
transcript
may
induc
respons
infecti
challeng
return
baselin
level
follow
pathogen
clearanc
dynam
chang
cellular
make
tissu
also
eff
ect
chang
transcript
abund
measur
genomewid
scale
transcript
profi
le
obtain
mani
human
tissu
includ
instanc
skin
muscl
liver
kidney
brain
statu
immun
system
best
monitor
profi
ling
transcript
abund
blood
inde
profi
ling
transcript
abund
blood
provid
snap
shot
complex
immun
network
oper
throughout
entir
bodi
howev
proven
valid
approach
fi
nding
clue
number
highthroughput
molecular
cellular
profi
ling
tool
use
profi
le
human
immun
system
increas
rapidli
proteom
assay
use
determin
antibodi
specifi
citi
measur
chang
serum
level
cytokin
chemokin
use
multiplex
assay
cellular
profi
ling
assay
use
phenotyp
immun
cell
base
intracellular
extracellular
marker
use
polychromat
fl
ow
cytometri
vitro
cellular
assay
measur
innat
antigenspecifi
c
respons
cell
expos
immunogen
factor
genom
approach
consist
measur
abund
cellular
rna
also
microrna
present
cell
serum
genom
approach
consist
determin
gene
sequenc
function
exampl
genomewid
associ
studi
rna
interfer
screen
exom
sequenc
patho
genesi
well
identifi
potenti
biomark
number
challeng
limit
exist
data
interpret
one
firstli
volum
data
gener
studi
overwhelm
necessari
integr
inform
multitud
sourc
studi
design
qualiti
control
data
sampl
inform
importantli
clinic
inform
order
result
interpret
secondli
chang
transcript
abund
observ
complex
tissu
blood
caus
regul
gene
transcript
activ
also
rel
chang
abund
cell
popul
express
transcript
constant
level
th
irdli
addit
pathogen
process
number
factor
may
aff
ect
blood
transcript
abund
confound
analysi
medic
comorbid
two
factor
often
restrict
patient
select
complic
data
interpret
th
review
discuss
strategi
recent
develop
address
limit
realtim
pcr
technolog
current
consid
gold
standard
analysi
gene
express
howev
use
measur
abund
limit
number
transcript
introduc
year
ago
dna
microarray
routin
use
measur
transcript
abund
genomewid
scale
th
technolog
reli
dens
array
oligonucleotid
probe
captur
complementari
sequenc
present
biolog
sampl
variou
concentr
th
e
probe
deposit
solid
surfac
print
microarray
synthes
situ
aff
ymetrix
genechip
bound
glass
bead
lodg
well
etch
surfac
glass
slide
illumina
beadarray
th
e
label
materi
captur
microarray
imag
rel
abund
determin
base
strength
signal
produc
oligonucleotid
featur
note
provid
mean
survey
transcript
abund
genomewid
scale
sensit
microarray
assay
low
compar
approach
realtim
pcr
microarray
fulli
quantit
assay
chang
transcript
abund
must
measur
refer
control
sampl
need
includ
studi
howev
limit
may
lift
method
reli
highthroughput
sequenc
genomewid
measur
rna
abund
build
legaci
sage
serial
analysi
gene
express
technolog
introduc
rna
sequenc
rnaseq
use
either
total
fraction
rna
exampl
poli
start
point
th
materi
convert
librari
cdna
fragment
high
throughput
sequenc
fragment
yield
short
sequenc
read
typic
bp
length
depend
technolog
platform
use
given
sampl
ten
million
sequenc
uniqu
map
refer
genom
th
e
higher
level
express
given
gene
higher
number
read
align
figur
th
us
approach
reli
probe
design
provid
sever
type
inform
includ
transcript
abund
also
transcriptom
structur
splice
variant
profi
le
noncod
rna
speci
genet
polymorph
rnaseq
expect
becom
suffici
costeff
ectiv
practic
eventu
supersed
microarray
technolog
technolog
consid
profi
ling
focus
set
gene
nanostr
technolog
instanc
detect
abund
transcript
high
sensit
th
e
approach
digit
sinc
count
individu
rna
molecul
use
string
fl
uorochrom
report
identifi
diff
erent
rna
speci
technolog
platform
develop
among
other
luminex
high
th
roughput
genom
fluidigm
round
ere
subgenom
transcript
profi
ling
th
e
fi
eld
autoimmun
proven
fertil
ground
blood
transcript
studi
alter
transcript
abund
blood
patient
refl
ect
sustain
respons
selfantigen
gener
uncon
troll
infl
ammatori
process
diseas
often
present
recurringremit
pattern
activ
episod
fl
are
may
refl
ect
fl
uctuat
transcript
abund
th
e
work
initi
focus
diseas
clear
system
involv
system
lupu
erythematosu
sle
multipl
cell
type
solubl
mediat
includ
propos
center
lupu
pathogenesi
scatter
evid
indic
potenti
role
type
interferon
lupu
sever
observ
support
hypothesi
fi
rst
everi
sle
patient
detect
serum
type
ifn
level
second
dysregul
typei
ifn
product
found
murin
slemodel
third
genet
linkag
associ
studi
identifi
ed
candid
lupu
suscept
gene
within
ifn
pathway
howev
one
earliest
microarray
studi
demonstr
one
pediatr
patient
exhibit
upregul
ifninduc
gene
patient
lack
signatur
remiss
year
addit
found
treat
sle
patient
high
dose
iv
steroid
use
control
diseas
fl
are
result
silenc
ifn
signatur
surpris
initi
studi
absenc
type
ifn
gene
transcript
face
abund
ifninduc
one
blood
cell
sle
patient
like
explan
cell
produc
type
ifn
therefor
transcrib
gene
migrat
site
injuri
altogeth
result
microarray
studi
play
key
role
convinc
commun
potenti
import
type
ifn
sle
pathogenesi
phase
ia
trial
evalu
safeti
pharmacokinet
immunogen
monoclon
antibodi
mab
therapi
adult
sle
patient
recent
conduct
th
e
antibodi
elicit
specifi
c
dosedepend
inhibit
overexpress
type
ifninduc
gene
whole
blood
skin
lesion
sle
patient
transcript
protein
level
expect
overexpress
blysbaff
type
ifninduc
gene
also
decreas
treatment
th
us
fi
rst
trial
support
propos
central
role
type
ifn
human
sle
system
onset
juvenil
arthriti
sojia
anoth
diseas
system
involv
greatli
benefi
ted
studi
blood
transcript
profi
le
develop
therapeut
diagnost
modal
diseas
specifi
c
organ
involv
also
subject
signifi
cant
yet
alway
extens
blood
profi
ling
eff
ort
blood
signatur
instanc
obtain
patient
follow
extract
rna
use
templat
amplifi
ed
label
reaction
label
materi
captur
microarray
imag
rel
abund
determin
base
strength
signal
produc
fl
uorochrom
serv
report
assay
nanostr
technolog
measur
rna
abund
singl
molecul
level
rna
serv
start
materi
assay
involv
use
enzym
amplifi
cation
label
captur
report
probe
form
complex
solut
rna
molecul
complex
captur
solid
surfac
imag
molecul
count
gener
base
number
report
probe
detect
imag
report
consist
string
seven
fl
uorochrom
four
diff
erent
color
avail
fi
posit
diff
erent
transcript
detect
singl
reaction
platform
rna
sequenc
rnaseq
start
rna
popul
must
fi
rst
convert
librari
cdna
fragment
high
throughput
sequenc
fragment
yield
short
sequenc
read
typic
bp
length
given
sampl
ten
million
sequenc
uniqu
map
refer
genom
densiti
coverag
given
gene
determin
rel
level
express
similar
diff
erenc
technolog
platform
note
instanc
microarray
nanostr
technolog
reli
oligonucleotid
probe
captur
complementari
target
sequenc
nanostr
rnaseq
technolog
measur
abund
singl
molecul
level
result
express
molecul
count
sequenc
coverag
respect
microarray
rnaseq
technolog
requir
extens
sampl
process
includ
amplifi
cation
step
dsdna
doublestrand
dna
nanostr
rnaseq
multipl
sclerosi
given
inaccess
brain
blood
constitut
particularli
attract
sourc
surrog
molecular
marker
diseas
th
ese
eff
ort
yield
system
signatur
identifi
ed
potenti
predict
marker
clinic
relaps
respons
treatment
transcript
signatur
also
gener
context
dermatolog
diseas
case
target
organ
readili
access
eff
ort
focus
profi
ling
transcript
abund
skin
tissu
howev
system
involv
recogn
recent
year
import
compon
autoimmun
skin
diseas
uniqu
blood
transcript
profi
le
also
identifi
ed
patient
exampl
psoriasi
blood
transcript
profi
le
gener
context
mani
autoimmun
diseas
inde
rang
autoimmuneautoinfl
ammatori
diseas
investig
encompass
sle
juvenil
idiopath
arthriti
multipl
sclerosi
rheumatoid
arthriti
sjogren
syndrom
diabet
infl
ammatori
bowel
diseas
psoriasi
psoriat
arthriti
infl
ammatori
myopathi
scleroderma
vascul
antiphospholipid
syndrom
th
e
bodi
work
produc
focus
blood
transcript
profi
ling
context
autoimmun
diseas
cover
length
recent
review
global
chang
transcript
abund
also
measur
blood
patient
infecti
diseas
context
alter
blood
transcript
profi
le
refl
ection
immunolog
respons
mount
host
pathogen
th
respons
initi
special
receptor
express
surfac
host
cell
recogn
pathogenassoci
molecular
pattern
diff
erent
class
pathogen
signal
diff
erent
combin
receptor
elicit
turn
diff
erent
type
immun
respons
th
translat
experiment
distinct
transcript
program
induc
upon
exposur
immun
cell
vitro
distinct
class
infecti
agent
similarli
pattern
transcript
abund
measur
blood
patient
infect
caus
diff
erent
etiolog
agent
found
distinct
predict
dramat
chang
observ
blood
patient
system
infect
exampl
sepsi
howev
profound
alter
pattern
transcript
abund
also
found
patient
local
infect
exampl
upper
respiratori
tract
infect
urinari
tract
infect
pulmonari
tubercu
lo
si
skin
abscess
measur
chang
host
transcript
profi
le
may
therefor
prove
diagnost
valu
even
situat
caus
pathogen
agent
present
test
sampl
importantli
may
also
help
ascertain
sever
infect
monitor
cours
infect
often
present
acut
clinic
event
thu
import
captur
dynam
chang
transcript
abund
occur
cours
infect
time
initi
exposur
blood
signatur
describ
context
acut
infect
caus
wide
rang
pathogen
parasit
virus
bacteria
includ
plasmodium
respiratori
virus
infl
uenza
rhinoviru
respiratori
syncyti
viru
dengu
viru
adenoviru
well
salmonella
mycobacterium
tuberculosi
staphylococcu
aureu
burkholderia
pseudomallei
gener
context
bacteri
sepsi
pathogen
persist
establish
chronic
infect
exampl
human
immuno
defici
viru
plasmodium
may
lead
state
latenc
exampl
tuberculosi
transcript
profi
ling
may
use
situat
surveil
tool
monitor
diseas
progress
reactiv
blood
profi
ling
infecti
diseas
remain
limit
scale
particular
addit
studi
necessari
ascertain
dynam
chang
occur
time
addit
autoimmun
infecti
diseas
blood
transcript
profi
ling
studi
carri
cancer
research
fi
eld
hematolog
malign
led
way
review
blood
profi
le
also
obtain
recent
patient
solid
organ
tumor
notabl
signatur
refl
ect
immunolog
physiolog
chang
eff
ect
cancer
also
presenc
rare
tumor
cell
circul
blood
signatur
also
obtain
solid
organ
transplant
recipi
context
toler
graft
reject
signatur
also
detect
biopsi
materi
blood
er
distinct
advantag
access
safe
monitor
molecular
chang
routin
basi
work
also
done
context
cardiovascular
diseas
infl
ammat
known
play
import
role
henc
profi
le
identifi
ed
wide
rang
condit
includ
stroke
chronic
heart
failur
acut
coronari
syndrom
th
e
bodi
publish
work
larg
cite
review
like
tip
iceberg
lot
unpublish
data
scatter
public
privat
repositori
eff
ort
yield
instanc
blood
transcript
signatur
patient
neurodegen
diseas
associ
diseas
exacerb
respons
glucocorticoid
patient
asthma
respons
environment
exposur
exercis
even
laughter
unfortun
mani
publish
studi
underpow
sometim
lack
even
rudimentari
valid
step
often
primari
data
avail
reanalysi
either
refl
ect
lack
enforc
editori
polici
absenc
thereof
journal
henc
one
main
challeng
fi
eld
move
beyond
proof
principl
stage
consolid
wealth
data
gener
collect
studi
publish
thu
far
demonstr
alter
transcript
abund
detect
genomewid
scale
blood
patient
wide
rang
diseas
th
statement
far
trivial
given
skeptic
initi
met
studi
investig
blood
transcriptom
patient
also
learn
multipl
diseas
share
compon
blood
transcript
profi
le
instanc
case
infl
ammat
interferon
signatur
singl
element
profi
le
may
specifi
c
given
diseas
combin
element
make
signatur
uniqu
fi
nalli
work
accomplish
date
highlight
import
carri
analys
aim
directli
compar
transcript
profi
le
across
diseas
inde
much
learn
instanc
autoimmun
studi
respons
infect
vice
versa
furthermor
eff
ort
may
eventu
lead
us
closer
molecular
classifi
cation
diseas
first
howev
technolog
methodolog
advanc
necessari
blood
transcriptom
research
fi
eld
move
beyond
proof
principl
stage
recent
progress
blood
transcriptom
research
possibl
thank
develop
robust
sampl
collect
techniqu
introduct
high
throughput
gene
express
microarray
platform
advanc
necessari
margin
progress
fi
eld
still
signifi
cant
describ
current
hurdl
discuss
potenti
solut
overcom
year
scale
blood
transcript
studi
constrain
cost
technolog
price
tag
commerci
whole
genom
microarray
us
mark
case
anymor
th
us
data
manag
becom
fi
rst
essenti
step
make
larg
scale
molecular
profi
ling
viabl
proposit
beyond
store
output
microarray
instrument
data
manag
must
captur
organ
inform
essenti
interpret
result
figur
th
includ
sampl
inform
data
qualiti
metric
clinic
inform
collect
time
sampl
detail
experiment
design
materi
method
captur
inform
ensur
larg
volum
data
gener
often
publish
immedi
remain
exploit
year
come
th
point
becom
critic
given
fact
result
genomewid
profi
ling
studi
never
exploit
fullest
extent
possess
consider
cumul
valu
reanalyz
collect
notabl
result
gener
cellular
molecular
profi
ling
platform
also
need
integr
order
complet
pictur
th
erefor
implement
eff
ectiv
data
manag
solu
tion
practic
essenti
sustain
necessari
increas
scale
blood
transcript
studi
figur
unfortun
implement
data
manag
solut
laboratori
often
expens
proposit
requir
custom
theshelf
product
develop
custom
softwar
adapt
handl
specifi
c
workfl
ow
manag
data
also
take
time
requir
dedic
personnel
th
us
need
wide
perceiv
commit
step
necessari
implement
eff
ectiv
data
manag
solut
practic
rare
adopt
myriad
approach
develop
analysi
genomewid
transcript
profi
ling
data
howev
silver
bullet
come
microarray
data
analysi
th
e
challeng
encount
sever
fold
dimension
cope
fact
number
paramet
measur
exce
sever
order
magnitud
number
condit
includ
experi
nois
direct
consequ
fi
rst
point
result
microarray
analys
particularli
permiss
nois
fals
discoveri
see
data
data
visual
critic
help
promot
insight
support
data
interpret
biolog
context
import
keep
biolog
sight
time
inde
easi
becom
absorb
data
essenti
use
biolog
knowledg
design
analysi
strategi
final
hardli
onesizefi
tsall
approach
micro
array
data
analysi
work
one
situat
may
univers
applic
inde
common
respons
expert
question
best
way
analyz
given
dataset
depend
instanc
extent
diff
erenc
observ
variabl
inher
given
diseas
studi
popul
depend
question
ask
depend
whether
followup
confi
rmatori
experi
plan
tabl
provid
data
mine
primer
explain
basic
step
involv
microarray
data
analysi
consider
aris
ad
hoc
data
mine
approach
develop
meet
specifi
c
need
instanc
develop
data
mine
strategi
specifi
c
purpos
analyz
blood
transcript
profi
le
th
approach
simpli
consist
priori
group
set
gene
similar
transcript
pattern
th
repeat
sever
diff
erent
dataset
subsequ
compar
cluster
membership
gene
across
dataset
gene
similar
membership
figur
data
manag
key
progress
extens
cellular
molecular
profi
ling
human
subject
gener
vast
amount
dispar
data
eff
ectiv
data
manag
integr
solut
essenti
preserv
inform
interpret
form
thu
data
manag
eff
ort
occur
behind
scene
essenti
role
play
realiz
full
potenti
high
throughput
profi
ling
approach
human
subject
group
togeth
form
term
transcript
modul
structur
data
permit
focus
downstream
statist
test
set
transcript
form
coher
transcript
function
modular
unit
th
contrast
tradit
approach
reli
iter
statist
test
thousand
individu
transcript
treat
independ
variabl
th
e
modular
transcript
framework
develop
reduc
number
variabl
collaps
set
coordin
express
gene
new
entiti
modul
reduc
data
dimension
facilit
function
inter
pretat
enabl
compar
analys
across
multipl
dataset
diseas
minim
nois
improv
robust
biomark
signatur
yield
multivari
metric
use
bedsid
data
visual
also
critic
import
interpret
largescal
dataset
devis
straightforward
visual
scheme
map
global
transcript
chang
individu
diseas
modular
basi
figur
briefl
diff
erenc
express
level
studi
group
display
modul
grid
posit
grid
assign
given
modul
red
spot
indic
increas
blue
spot
decreas
transcript
abund
th
e
spot
intens
determin
proport
transcript
reach
signifi
canc
given
modul
posteriori
biolog
interpret
link
sever
modul
immun
cell
pathway
see
legend
figur
henc
exampl
provid
figur
provid
basic
analysi
step
import
consider
microarray
data
analysi
perchip
normal
step
control
arraywid
variat
intens
across
multipl
sampl
form
given
dataset
array
fl
uoresc
base
assay
subject
signal
variat
varieti
reason
includ
effi
cienci
label
hybrid
reaction
possibl
less
well
defi
ned
variabl
reagent
qualiti
sampl
handl
control
sampl
normal
fi
rst
subtract
background
employ
normal
algorithm
rescal
diff
erenc
overal
intens
fi
xed
intens
level
sampl
across
multipl
array
data
fi
ltere
typic
half
oligonucleotid
probe
present
microarray
detect
signal
sampl
given
analysi
thu
detect
fi
lter
appli
exclud
transcript
origin
dataset
step
avoid
introduct
unnecessari
nois
downstream
analys
unsupervis
analysi
aim
analysi
group
sampl
basi
molecular
profi
le
without
priori
knowledg
phenotyp
classifi
cation
fi
rst
step
function
second
detect
fi
lter
consist
select
transcript
express
dataset
display
degre
variabl
facilit
sampl
cluster
instanc
fi
lter
could
select
transcript
express
level
deviat
least
twofold
median
intens
calcul
across
sampl
importantli
addit
fi
lter
appli
independ
knowledg
sampl
group
phenotyp
make
type
analysi
unsupervis
next
pattern
discoveri
algorithm
often
appli
identifi
molecular
phenotyp
trend
data
cluster
cluster
commonli
use
discoveri
express
pattern
larg
dataset
hierarch
cluster
iter
agglom
cluster
method
use
produc
gene
tree
condit
tree
condit
tree
cluster
group
sampl
base
similar
express
profi
le
across
specifi
ed
gene
list
commonli
employ
cluster
algorithm
includ
kmean
cluster
selforgan
map
class
comparison
analys
identifi
gene
diff
erenti
express
among
studi
group
class
andor
time
point
method
analysi
chosen
base
studi
design
studi
independ
observ
two
group
ttest
anova
mannwhitney
u
test
kruskalw
test
use
linear
mix
model
analys
chosen
longitudin
studi
multipl
test
correct
multipl
test
correct
mtc
method
provid
mean
mitig
level
nois
set
transcript
identifi
ed
class
comparison
order
lower
permiss
fals
posit
reduc
nois
mtc
promot
higher
fals
neg
rate
result
dampen
signal
method
avail
character
vari
degre
stringenc
therefor
produc
gene
list
diff
erent
level
robust
bonferroni
correct
stringent
method
use
control
familywis
error
rate
probabl
make
one
type
error
drastic
reduc
fals
posit
rate
convers
increas
probabl
fals
neg
benjamini
hochberg
fals
discoveri
rate
less
stringent
mtc
method
provid
good
balanc
discoveri
statist
signifi
cant
gene
limit
fals
posit
use
procedur
valu
statist
signifi
cant
transcript
might
identifi
ed
signifi
cant
chanc
alon
fals
posit
class
predict
class
predict
analys
assess
abil
gene
express
data
correctli
classifi
studi
subject
sampl
knearest
neighbor
commonli
use
techniqu
task
avail
class
predict
procedur
includ
limit
discrimin
analysi
gener
linear
model
select
logist
regress
distanc
score
partial
least
squar
partit
tree
radial
basi
machin
sampl
size
number
sampl
necessari
identifi
cation
robust
signatur
variabl
inde
sampl
size
requir
depend
amplitud
diff
erenc
variabl
within
studi
group
number
approach
devis
calcul
sampl
size
microarray
experi
date
littl
consensu
exist
henc
best
practic
fi
eld
consist
util
independ
set
sampl
purpos
valid
candid
signatur
thu
robust
signatur
identifi
ed
reli
statist
signifi
cant
associ
predict
true
phenotyp
class
fi
rst
second
test
set
modul
also
note
chang
observ
modul
modul
includ
interferoninduc
gene
abund
would
increas
context
viral
infect
microrna
mirna
control
emerg
critic
regu
latori
circuit
immun
system
measur
chang
mirna
abund
blood
human
subject
health
diseas
therefor
promis
new
fi
eld
investig
th
ese
short
noncod
singlestrand
rna
nucleotid
length
found
play
essenti
regulatori
role
th
ese
molecul
exhibit
highli
specifi
c
regul
pattern
express
control
protein
express
tran
lation
repress
mrna
cleavag
promot
mrna
decay
interestingli
thank
small
size
mirna
molecul
stabl
measur
blood
cell
also
circul
serum
th
ey
thu
potenti
import
contributor
immun
function
also
potenti
sourc
biomark
blood
transcriptom
research
also
benefi
concep
tual
advanc
may
help
address
shortcom
inher
whole
blood
profi
ling
first
blood
complex
tissu
chang
transcript
abund
attribut
either
transcript
regul
rel
chang
composit
leukocyt
popul
two
approach
exist
deconvolut
two
phenomena
first
one
isol
individu
profi
le
diff
erent
cell
popul
present
blood
th
approach
may
also
permit
identifi
cation
transcript
express
low
level
detect
diff
erenc
express
would
otherwis
drown
whole
blood
howev
isol
method
may
introduc
technic
bia
requir
extens
sampl
process
second
approach
consist
deconvolut
whole
blood
transcript
profi
le
silico
th
type
analysi
attempt
deduc
cellular
composit
cellspecifi
c
level
gene
express
use
statist
methodolog
final
must
also
keep
mind
immun
statu
human
subject
entir
refl
ect
blood
profi
le
obtain
steadi
state
inde
individu
capac
respond
innat
well
antigenspecifi
c
immun
signal
may
also
provid
use
complementari
inform
conclus
blood
transcript
profi
ling
earn
place
molecular
cellular
profi
ling
armamentarium
use
studi
human
immun
system
chang
transcript
abund
recapitul
infl
uenc
genet
epigenet
cellular
environ
mental
factor
initi
consid
belong
cut
edg
approach
becom
robust
practic
discuss
review
becom
mainstay
studi
immun
function
patient
wide
rang
diseas
furthermor
recent
studi
demonstr
util
blood
transcriptom
profi
ling
monitor
immun
respons
drug
vaccin
th
us
blood
transcript
profi
ling
develop
rel
chang
transcript
abund
blood
patient
aureu
infect
compar
healthi
control
record
set
transcript
modul
color
spot
repres
rel
increas
red
decreas
blue
transcript
abund
p
mann
whitney
within
modul
legend
show
function
interpret
set
modul
fingerprint
gener
two
independ
cohort
subject
divid
train
set
use
discoveri
phase
n
independ
test
set
use
valid
phase
n
mainstream
tool
assess
statu
human
immun
system
